Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 116, Issue , 2016, Pages 1-6

  Tanaka, Sayuri ^a   Kanazawa, Ippei ^a   Notsu, Masakazu ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Dipeptidyl peptidase 4; Metabolic syndrome; Type 2 diabetes mellitus; Visceral fat

Indexed keywords

CREATININE; DIPEPTIDYL PEPTIDASE IV; HEMOGLOBIN A1C; DPP4 PROTEIN, HUMAN;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE DURATION; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SUBCUTANEOUS FAT; AGED; BLOOD; COMPLICATION; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGAN SIZE; STATISTICAL MODEL; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; HUMANS; INTRA-ABDOMINAL FAT; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY, ABDOMINAL; ORGAN SIZE; SUBCUTANEOUS FAT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84966271186     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.04.027     Document Type: Article

References (25)

1. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
2. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008, 60:470-512.
3. Mulvihill E.E., Drucker D.J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 2014, 35:992-1019.
4. Nauck M., Stockmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
5. Kendall D.M., Cuddihy R.M., Bergenstal R.M. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009, 122:S37-S50.
6. Maeda K., Okubo K., Shimomura I., Mizuno K., Matsuzawa Y., Matsubara K. Analysis of an expression profile of genes in the human adipose tissue. Gene 1997, 190:227-235.
7. Fasshauer M., Bluher M. Adipokines in health and disease. Trends Pharmacol Sci 2015, 36:461-470.
8. Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., Ouwens D.M., et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011, 60:1917-1925.
9. Sell H., Bluher M., Kloting N., Schlich R., Willems M., Ruppe F., et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 2013, 36:4083-4090.
10. Aso Y., Ozeki N., Terasawa T., Naruse R., Hara K., Suetsugu M., et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl Res 2012, 159:25-31.
11. Lee S.A., Kim Y.R., Yang E.J., Kwon E.J., Kim S.H., Kang S.H., et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013, 98:2553-2561.
12. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y., Nanjo K., Tajima N., Kadowaki T., Kashiwagi A., et al. Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010, 1:212-228.
13. Kanazawa I., Tanaka S., Notsu M., Sugimoto T. Pioglitazone increases serum DPP-4 level in type 2 diabetes mellitus. Journal of Diabetes & Metabolism 2014, 5:416.
14. Notsu M, Kanazawa I, Tanaka S, Yamaguchi T, Sugimoto T. Serum dipeptidyl peptidase-4 is associated with multiple vertebral fractures in type 2 diabetes mellitus. Clin Endocrinol, Epub ahead of print.
15. Kanazawa I., Yamaguchi T., Yamauchi M., Yamamoto M., Kurioka S., Yano S., et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 2011, 22:187-194.
16. The Examination Committee of Criteria for Metabolic syndrome The definition and criteria of metabolic syndrome. Nihon Naika Gakkai Zasshi (J Jpn Soc Int Med) 2005, 94:794-809. (In Japanese).
17. Yamaguchi T., Kanazawa I., Yamamoto M., Kurioka S., Yamauchi M., Yano S., et al. Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Bone 2009, 45:174-179.
18. Bando Y., Kanehara H., Aoki K., Hisada A., Toya D., Tanaka N. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients. J Diabetes Investig 2012, 3:170-174.
19. Kim Y.G., Hahn S., Oh T.J., Kwak S.H., Park K.S., Cho Y.M. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systemic review and meta-analysis. Diabetologia 2013, 56:696-708.
20. Vazzana N., Santilli F., Sestili S., Cuccurullo C., Davi G. Determinants of increased cardiovascular disease in obesity and metabolic syndrome. Curr Med Chem 2011, 18:5267-5280.
21. Zheng T., Baskota A., Gao Y., Chen T., Tian H., Yang F. Increased plasma DPP-4 activities predict new-onset hyperglycemia in Chinese over a four-year period: possible associations with inflammation. Metabolism 2015, 64:498-505.
22. Tremblay A.J., Lamarche B., Deacon C.F., Weisnagel S.J., Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism 2014, 63:1141-1148.
23. Fujimoto W.Y. Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups. Diabet Med 1996, 13:S7-S10.
24. Busso N., Wagtmann N., Herling C., Chobaz-Peclat V., Bischof-Delaloye A., So A., et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005, 166:433-442.
25. Kobayashi H., Hosono O., Mimori T., Kawasaki H., Dang N.H., Tanaka H., et al. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J Rheumatol 2002, 29:1858-1866.